anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Neuroimaging studies suggest that high rate of smoking in patients with schizophrenia may be due to an overlap of nicotine addiction related circuitries and schizophrenia related circuitries, such that schizophrenia impact some of the same circuitries that increase risks for severe nicotine addiction in general. Those identified overlapping circuitries have been linked to several key features of nicotine addiction and can be represented by resting state functional connectivities. Transcranial magnetic stimulation (TMS) provides a non-invasive means for altering brain electrical neural activity. TMS has been approved by FDA for treatment of depression. Other applications have not been approved but it has been used in a wide range of clinical research especially in neurology and psychiatry. There are preliminarily significant improvements in treatments of smoking cessation in schizophrenia using TMS with small samples, but those treatments are not robust in larger samples. The high inter-subject variability limits the efficacy of TMS treatment in schizophrenia patients. We aim to develop a TMS method targeting special brain circuits that are both smoking cessation and schizophrenia related. If the corresponding brain circuits were successfully modulated, the treatment efficacy will be significantly improved and schizophrenia patients will benefit from the TMS treatment of smoking cessation.
Femoroacetabular impingement (FAI) is a condition of the hip where there is a mismatch of the ball and socket in the hip joint. This mismatch creates abnormal contact in the hip which can cause patients to experience hip pain. This can eventually lead to hip damage and osteoarthritis. Hip arthroscopy, a form of minimally invasive surgery has become a popular treatment option. The investigators are conducting a definitive randomized controlled trial (RCT) to determine whether surgical correction of the impingement morphology via arthroscopic osteochondroplasty (shaving of bone) will provide improved clinical results (decreased pain and improved function) in adult FAI patients compared to arthroscopic lavage (washing out of painful inflammation debris) and treating obvious damage of the hip joint.

Like most RCTs, FIRST is designed to demonstrate efficacy (i.e. that an intervention can work theoretically under optimal conditions). In order to address generalizability and improve external validity of the FIRST trial, we are including an external validation cohort using a "RCT with and Embedded ProspectIve Cohort design" (FIRST-EPIC). This pragmatic cohort will allow us to: 1) safeguard against bias attributable to patients declining to take part in the RCT; 2) corroborate or refute whether our efficacy (RCT) population represents the best case scenario (i.e. those with optimal response to osteochondroplasty); 3) evaluate effectiveness of osteochondroplasty and other standard of care treatments for FAI in patients with potentially distinct prognostic factors; and 4) evaluate the cost-effectiveness of the interventions.
The optimal dose weekly bi-daily oral docetaxel - ModraDoc006 10 mg in combination with ritonavir will be determined with a classical dose escalation design. Approximately 24 patients will be enrolled depending on required number of dose levels before MTD is reached.
The present invention relates to a pharmaceutical composition and health-aid food including pollen of Actinidia arguta as an active ingredient for preventing or treating thrombosis. Particularly, the present invention relates to a pharmaceutical composition and health-aid food including ethyl acetate fraction, butanol fraction, residue in water after fractionation of ethanol extract of pollen of Actinidia arguta, or a mixture thereof, as an active ingredient for preventing, treating/alleviating thrombosis through inhibition of blood coagulation and inhibition of platelet aggregation. The extract of pollen of Actinidia arguta as an active ingredient of the pharmaceutical composition and health-aid food for preventing or treating thrombosis inhibits thrombogenesis-related enzymes and blood coagulation factors and also inhibits platelet aggregation functioning to initiate thrombogenesis, thereby providing strong anti-thrombotic activity. In addition, the extract of pollen of Actinidia arguta shows no hemolysis to human red blood cells, has excellent heat stability and causes no loss of the effect of inhibiting blood coagulation factors and thrombogenesis-related enzymes, and thus is expected to be used to prevent and treat thrombosis, such as ischemic stroke and hemorrhagic stroke, by improving blood circulation, even under an acidic condition of pH 2 and in the plasma. The active ingredient can be processed into various shapes, such as extract, powder, pills and tablets, and prepared into forms that can be administered at all times. Therefore, the present invention is useful in the field of pharmaceutical and food industries.
FIELD: production of radionuclides for medicine and technology. SUBSTANCE: generator has sorbent and radioisotope holding column installed inside radiation shield and generator housing, flange with seats placed above radiation shield, elutriate, eluate, and air bactericidal filter needles connected through flexible hoses to column, air bactericidal filter, elutriate tank, and selector switch. The latter is, essentially, four-way cock with control valve and is placed in seat of flange with needles for elutriate and air bactericidal filter and connected through flexible hoses to filter, cover, and bottom of elutriate tank and to column entrance. Selector switch control valve has three locked positions relative to cock body; neutral; elutriate tank-to-column; air bactericidal filter-to-column. Elutriate tank is annular space, such as torus, or double-walled cylinder placed around radiation shield. EFFECT: improved efficiency of radioisotope removal from sorbent during elution process. 2 cl, 3 dwg
This study will be a prospective pilot enrolling 10 patients with advanced disease admitted to the heart failure service at St. Luke's Mid America Heart Institute and who are not candidates for advanced therapies such as heart transplant or mechanical circulatory support (left ventricular assist device). Potential enrollees will be identified using a validated risk model that predicts death or poor quality of life in the six months after discharge from the hospital for heart failure exacerbation. Enrolled patients will complete validated questionnaires while still hospitalized, regarding health-related quality of life, illness acceptance, prioritization of different life goals, and confidence in decision-making regarding their terminal heart failure. Patients will then be given a paper exercise regarding delineation of an end-of-life plan and appointment of a surrogate medical decision-maker, to be completed after discharge. At their regularly scheduled admission follow-up visit with seven days of discharge, participants will be asked to bring their medical decision maker and participate in a semi-structured supplemental palliative care/education session facilitated by a heart failure nurse practitioner trained in palliative care discussions. Domains included in the intervention will include disease literacy and understanding, goals of care, legal issues for patients with terminal illness, symptom management, health-related quality of life, caregiver burden, patient autonomy, healthcare utilization, and establishment of end-of-life plans.

Outcomes to be measured after the intervention include repeated validated questionnaires and unstructured patient interviews at 1 month and, at 6 months, creation of a formalized end-of-life plan, change in code status, obtainment of an advanced directive, designation of a durable power of attorney, frequency of re-hospitalizations, emergency room visits and unscheduled clinic visits with providers, and death. These will be obtained at the time of regularly scheduled heart failure clinic follow-up visits or over the phone.
The Parent Patent described the prepn. of an antihaemophilic globulin A (factor VIII) contg. concentrate together with a prothrombin complex (Factors II, VII, IX and X) and a soln. of storage stable serum protein, using a frozen ion exchanger plasma as starting material, which had been thawed at 2-8 degrees C and in which the supernatant plasma liq. had been sepd. from the Factor VIII-contg. protein ppte. to give a Factor VIII concentrate after work up of this cryoppte. The plasma liq. was freed from Factors II, VII, IX and X by adsorption over commercial tricalcium phosphate. Any coagulation factors or other unstable proteins remaining in the plasma liq. were adsorbed over colloidal silica gel of specific surface 50x400m2/g. A storage stable serum protein remained. In this addition, the starting material is a citrate plasma, and after thawing and sepg. the cryoppte, the supernatant is treated with a polystyrene/dibenzene/quat. amine anion exchange resin and polystyrene/sulphonate cation exchange resin. Three hepatitis-safe and therapeutic prods. can be obtd. from blood plasma stabilised with citrate as well as a fourth prod., fibrinogen. The amt. of coagulation is reduced. Citrate blood from plasmapheresis and blood donors can be used, because the disadvantages associated with the addition of the stabiliser are removed by the treatment with the ion exchangers.
OBJECTIVE: In this retrospective study, the authors aimed to establish the stereotactically defined probability distribution for speech (i.e., anarthria, speech arrest) and lexico-semantic errors (i.e., anomia) through direct cortical stimulation (DCS) by using two tasks: action naming and object naming. They also analyzed the patterns of interindividual variability in the localization of the language sites involved, and investigated whether any patient or lesion location factors were associated with greater variability.
METHODS: Eighty-one Italian-speaking patients who underwent awake surgery between 2010 and 2021 for low- and high-grade gliomas in eloquent areas of the language-dominant hemisphere were entered in the analyses. The intraoperative DCS protocol included automatic speech tasks, object naming, and action naming. The position of the tags, as depicted on the intraoperative video or photograph, was transposed into Montreal Neurological Institute space. Subsequently, a 2D scatterplot and cluster analysis were performed. Associations between various clinical and radiological characteristics and the quantity of positive stimulated sites were determined by univariate analyses using binary logistic regression. Associated variables (p < 0.2) were included in stepwise multivariate logistic regression with backward elimination (p < 0.05).
RESULTS: A total of 1380 cortical sites were stimulated, with a positive response in 511 cases (37%). Most anarthric errors were triggered when stimulating the left precentral gyrus, and most speech arrest errors were elicited when stimulating the left posterior inferior frontal gyrus. Anomias were found in the left inferior frontal gyrus and in the posterior part of the left temporal lobe for object naming. DCS to the left dorsal premotor cortex elicited anomic errors for action naming. Anomias were also elicited during DCS to the left posterior temporal lobe, with both object and action naming.
CONCLUSIONS: The distribution of speech and lexico-semantic errors is in line with the current literature. The action-naming results are new and mostly involve the dorsal premotor cortex. These findings stress the importance of maximizing the use of different language tasks during surgery, because even when looking for the same type of errors, different tasks may be better suited to map specific brain regions. DCS with action and object naming identifies more positive sites than object naming alone.
A class of polypeptides useful in an in vitro diagnosis of Mycoplasma infection in animals is disclosed. These polypeptides are also capable of inducing an immune response in swine which were previously not exposed to Mycoplasma. The polypeptides consist of a 50kd antigenic protein and various truncations of this protein as well as a B-galactosidase fusions. Further, various polypeptide fragments are provided in addition to 5' DNA sequences for the genomic clones. Expression is in E. Coli. Recombinant DNA methods for the production of these polypeptides and certain phage vectors useful in these methods are also disclosed. Methods of vaccinating animals utilizing a vaccination composition which includes these polypeptides is also disclosed.
AIMS: Intramuscular hemangioma capillary type (IHCT) is a rare entity that refers to fast-flow vascular lesions. This study aims to elucidate the relationships between clinicopathological, radiological, and molecular characteristics in IHCT patients.
METHODS AND RESULTS: We reviewed all IHCT cases which were treated surgically in our pathology database from 2014 to 2023. Ten cases were analyzed via next-generation sequencing (NGS) and Sanger sequencing. The cohort consisted of 10 patients (6 males, 4 females) with a median age of 18 years (range: 1-37). Disease lesions were located in the trunk (n = 4), upper extremity (n = 2), lower extremity (n = 2), shoulder (n = 1), and neck (n = 1). IHCT is most commonly a progressively increasing painless mass. Histopathologically, all lesions exhibited aggregates, lobules, and anastomosing cords of capillary-type vessels separating or infiltrating the skeletal muscles. Four cases exhibited irregularly dilated vessels with thick walls, such as arteriovenous malformations (AVM) in the lesion's periphery. MRI findings commonly demonstrated a well-delineated, homogeneous mass. Somatic mutations were detected in seven of the ten IHCT cases. Four cases harbored mutations in MAP2K1 (p.Q58_E62del, p.K57_G61del, p.K57 N), two cases harbored mutations in KRAS (p.Q61R and p.L56V, p.G13R), and one case harbored a mutation in HRAS (p.D69_Q70insRWYSAMRD). Mutant allele frequencies detected by sequencing ranged from 9.98% to 15.97%.
CONCLUSIONS: The hemodynamic and molecular genetic phenotypes of IHCT closely resemble those observed in AVMs. Newly identified KRAS missense mutations, including cases with coexisting mutation types, and HRAS insertion mutations offer valuable insights into the genetic basis of vascular anomalies. These findings may also present potential targets for the development of novel pharmacotherapeutic interventions.
To compare the efficacy of adding diluted budesonide lavage to maximal clinical treatment, the placebo group is used. The placebo formula is composed of 1% glycerin diluted in water.
A one time use disposable paper soap. The soap includes a substrate, a cleaning composition, and a holder. The disposable paper is dissolvable in water. The cleansing composition is impregnated in the substrate so as to form a dry and cleanser impregnated substrate is not laid hold on to prevent exposure and evaporation of the cleansing composition, since the and cleanser impregnated substrate is dry. The holder removably holds at least one stacked dry and cleanser impregnated substrate. When the dry and cleanser impregnated substrate is removed from the holder and subjected to water, the substrate dissolves leaving the cleansing composition dissolved in the water for cleansing.
The invention discloses a method and a device for segmenting a polyp image semantic. The device comprises an acquisition module, a segmentation module and a display module. The using method comprises the following steps: the acquisition module acquires the enteroscope video and converts the enteroscope video into image frames. The segmentation module preprocesses the converted image, removes a reflective part, inputs the image into an Ext-HarDNet network consisting of an encoder, a middle layer and a decoder, abandons shallow layer characteristics of the image, extracts attention characteristics corresponding to deep layer characteristics, and performs bilinear sampling after characteristic fusion. And displaying the obtained segmentation result by a display module. The method can overcome the problems of picture compression and modules caused by a mainstream reflection removing method, and the HarDNet framework with low flow is used for constructing the backbone network, so that the speed can be improved, and the real-time property can be met. The middle layer may enforce global feature ties. The fusion method of the decoder can improve the proportion of the effective receptive field. And finally, realizing accurate and rapid segmentation of the polyp image.
The SOC for ART adherence consists of viewing a 20-minute animated tutorial which explains the importance of adherence to antiretroviral medication. It is specifically designed for viewers who have no science background and is appropriate for adolescents and young adults.
Autism spectrum disorders (ASDs) are developmental disorders with similar features, including problems communicating, problems interacting socially, and the presence of routines or repetitive behaviors. These disorders can have a range of severities. They include autistic disorder, Asperger's syndrome, and pervasive developmental disorder not otherwise specified (PDD-NOS). In addition to their core impairment in social functioning, children and adolescents with ASDs often have anxiety about social interactions, which compounds their difficulties and can limit the benefits of treatment. This study will develop and test a treatment program for developing social skills and reducing anxiety in children and adolescents with ASDs.

Participation in this study will last 12 to 14 weeks, with follow-up visits occurring 3 and 12 months after that. Participants will be randomly assigned to receive the treatment program either immediately or after being on a wait list. The treatment program will consist of 12 to 14 weekly individual therapy sessions that teach children and adolescents about ASDs, use cognitive-behavioral interventions to address problematic thinking and acting, deliver social skills instruction, and give opportunities to practice skills-including some practice outside the clinic in naturalistic settings. Every 2 weeks, starting at Week 4, children and adolescents will also attend group sessions to discuss strategies and practice social skills. Parents of the participants will be included at the end of each individual session for several minutes. After the participants assigned to immediate treatment complete the program, participants from the wait list will be offered the treatment.

Child and adolescent participants and their parents will complete assessments at baseline, midpoint in treatment, post-treatment (Week 12 or 14), and 3- and 12-month follow-ups. Participants assigned to the wait list condition will complete assessments only at baseline, before entering treatment (Week 12 or 14), and after completing treatment. Assessments will involve questionnaires about social and emotional functioning, interviews with study researchers, and surveys on satisfaction with the study. The child or adolescent's primary teacher will also complete questionnaires about the child.
Immediate release (IR) tramadol has demonstrated efficacy in several pain conditions including: obstetrical, gynecological, orthopedic, abdominal, and oral surgery. The short elimination half-life of tramadol IR necessitates every 4-6 hour dosing to maintain optimal levels of analgesia in chronic pain. The study medication in this study is a once-daily, extended-release tramadol formulation. This is a 12-week multi-center, double-blind, randomized, dose-ranging, parallel-group, fixed-dose, placebo-controlled study. Patients with OA Functional Class I-III of the knee or hip (index joint) are eligible for participation, if appropriate criteria are met. During a 2-7 day washout period, the use of all analgesic medications will be discontinued. Eligible patients experiencing moderate to severe pain (\<=40 mm on a 100 mm visual analog scale) in the index joint to be evaluated and who meet all other study criteria will enter in a 2-week,double-blind titration period. During this period, patients will be randomly assigned to receive treatment with tramadol HCl ER 100 mg, 200 mg, 300 mg, 400 mg or placebo, once a day. Patients will be titrated to their assigned dose between study days 1 - 15 and will continue at that dose for the remainder of the study (Week 12). Efficacy and safety evaluations will be collected at study visits occurring at Weeks 1, 2, 3, 6, 9 and 12 or at early termination. Study medication will be discontinued at Week 12 and patients will return after 1 week for a post-treatment visit (Week 13). Patients with unmanageable pain or with unacceptable side effects will be discontinued from the study and alternate analgesic therapy initiated, as appropriate.
PURPOSE: To obtain a new pyripyropene derivative useful for treating adult diseases caused by cholesterol accumulation in humans such as hyperlipemia or arteriosclerosis based thereon. CONSTITUTION: This pyripyropene derivative of the formula [R1 , R2 and R3 are each H or an O-acyl O-acetyl)]. The derivative is obtained by separating and purifying a substance having inhibiting activities against acyl-coenzyme A (CoA)-cholesterol acyltransferases from a cultured product of an FO-1289 strain, removing nicotinic acid from the resultant pyripyropene in a solvent such as a hydrous alcohol with a nucleophilic reagent such as sodium methoxide and further, as desired, acylating the prepared compound with an acid anhydride or an acid chloride and a base (e.g. pyridine) in a solvent such as pyridine or acylating the pyripyropene according to condensing reaction with a carboxylic acid in the presence of a condensing agent (e.g. dicyclohexylcarbodiimide) and a base (e.g. dimethylaminopyridine) in a solvent such as dichloromethane.  All the reactions are preferably carried out at ambient temperature.